NSC logoThe cost of publication in Journal of Biomedical Science is borne by the National Science Council, Taiwan.

Open Access Highly Accessed Research

Pyrazole compound BPR1P0034 with potent and selective anti-influenza virus activity

Shin-Ru Shih13, Tzu-Yun Chu2, Gadarla Randheer Reddy4, Sung-Nain Tseng13, Hsiun-Ling Chen2, Wen-Fang Tang2, Ming-sian Wu2, Jiann-Yih Yeh4, Yu-Sheng Chao4, John TA Hsu45, Hsing-Pang Hsieh4* and Jim-Tong Horng23*

Author Affiliations

1 Department of Medical Biotechnology and Laboratory Science, Chang Gung University, Taoyuan 333, Taiwan

2 Department of Biochemistry, Chang Gung University, Taoyuan333, Taiwan

3 Research Center for Emerging Viral Infections, Chang Gung University, Taoyuan 333, Taiwan

4 Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli 350, Taiwan

5 Department of Biological Science and Technology, National Chiao Tung University, Hsinchu 300, Taiwan

For all author emails, please log on.

Journal of Biomedical Science 2010, 17:13  doi:10.1186/1423-0127-17-13

Published: 23 February 2010



Influenza viruses are a major cause of morbidity and mortality around the world. More recently, a swine-origin influenza A (H1N1) virus that is spreading via human-to-human transmission has become a serious public concern. Although vaccination is the primary strategy for preventing infections, influenza antiviral drugs play an important role in a comprehensive approach to controlling illness and transmission. In addition, a search for influenza-inhibiting drugs is particularly important in the face of high rate of emergence of influenza strains resistant to several existing influenza antivirals.


We searched for novel anti-influenza inhibitors using a cell-based neutralization (inhibition of virus-induced cytopathic effect) assay. After screening 20,800 randomly selected compounds from a library from ChemDiv, Inc., we found that BPR1P0034 has sub-micromolar antiviral activity. The compound was resynthesized in five steps by conventional chemical techniques. Lead optimization and a structure-activity analysis were used to improve potency. Time-of-addition assay was performed to target an event in the virus life cycle.


The 50% effective inhibitory concentration (IC50) of BPR1P0034 was 0.42 ± 0.11 μM, when measured with a plaque reduction assay. Viral protein and RNA synthesis of A/WSN/33 (H1N1) was inhibited by BPR1P0034 and the virus-induced cytopathic effects were thus significantly reduced. BPR1P0034 exhibited broad inhibition spectrum for influenza viruses but showed no antiviral effect for enteroviruses and echovirus 9. In a time-of-addition assay, in which the compound was added at different stages along the viral replication cycle (such as at adsorption or after adsorption), its antiviral activity was more efficient in cells treated with the test compound between 0 and 2 h, right after viral infection, implying that an early step of viral replication might be the target of the compound. These results suggest that BPR1P0034 targets the virus during viral uncoating or viral RNA importation into the nucleus.


To the best of our knowledge, BPR1P0034 is the first pyrazole-based anti-influenza compound ever identified and characterized from high throughput screening to show potent (sub-μM) antiviral activity. We conclude that BPR1P0034 has potential antiviral activity, which offers an opportunity for the development of a new anti-influenza virus agent.